Part 1 Levulan surface application twice with microneedling ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
34. Neurofibromatosis
Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01682811 (ClinicalTrials.gov) | March 12, 2012 | 5/9/2012 | Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1) | Photodynamic Therapy for Benign Dermal Neurofibromas Using Levulan Kerastick For Topical Solution, Plus Illumination With Red Light | Neurofibromatoses | Drug: Part 1 Levulan injection;Drug: Part 1 Levulan surface application;Drug: Part 1 Levulan surface application twice;Drug: Part 1 Levulan surface application twice with microneedling;Drug: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1;Drug: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2;Drug: Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3 | Harry T Whelan, MD | NULL | Completed | 18 Years | 90 Years | All | 20 | Phase 1 | United States |